Trial Profile
A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Biliary cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Lung cancer; Ovarian cancer; Salivary gland cancer; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- 06 Jun 2023 Primary endpoint has not been met (Overall response rate (ORR) in patients with HER2 mutant - in patients with HER2 amplified endometrial, colorectal and other cancers) , according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Primary end-point (Overall response rate (ORR) in patients with HER2 mutant in salivary gland cancer) has been met, according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results of final analysis presented at the 59th Annual Meeting of the American Society of Clinical Oncology